Initial toxicity assessment of ICON6: a randomised trial of cediranib plus chemotherapy in platinum-sensitive relapsed ovarian cancer

BACKGROUND: Cediranib is a potent oral vascular endothelial growth factor (VEGF) signalling inhibitor with activity against all three VEGF receptors. The International Collaboration for Ovarian Neoplasia 6 (ICON6) trial was initiated based on evidence of single-agent activity in ovarian cancer with...

Descripción completa

Detalles Bibliográficos
Autores principales: Raja, F A, Griffin, C L, Qian, W, Hirte, H, Parmar, M K, Swart, A M, Ledermann, J A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2011
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3185949/
https://www.ncbi.nlm.nih.gov/pubmed/21878941
http://dx.doi.org/10.1038/bjc.2011.334

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3185949/
https://www.ncbi.nlm.nih.gov/pubmed/21878941
http://dx.doi.org/10.1038/bjc.2011.334

Ejemplares similares